CLBS - カラドリアス・バイオサイエンス (Caladrius Biosciences Inc.) カラドリアス・バイオサイエンス



symbol CLBS
会社名 Caladrius Biosciences Inc (カラドリアス・バイオサイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Hospital/Nursing Management  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Caladrius Biosciences Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company''s lead product candidate CLBS03 is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient''s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study a Phase II prospective randomized placebo-controlled double-blind clinical trial to evaluate its Treg product candidate CLBS03 in adolescents with recent onset T1D. The Company plans to develop its product candidate CLBS12 in Japan which is an autologous therapy that derives its cells from peripheral blood through apheresis.   カラドリアス・バイオサイエンスは米国のバイオテクノロジ―企業。独自の細胞治療製品の開発に従事し、再生医療分野でのサ―ビスを提供する。虚血に対処するための治療法の開発、急性心筋梗塞後の損傷した心筋を治療、免疫系の不均衡によって引き起こされる疾患を治療、テクノロジ―再生医療プラットフォ―ムなどがある。   Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
本社所在地 106 Allen Road Fourth Floor Basking Ridge NJ 07920 USA
代表者氏名 David J. Mazzo デビットJ.マッツォ
代表者役職名 Chief Executive Officer Independent Director
電話番号 +1 908-842-0100
設立年月日 29465
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 221人
EBITDA EBITDA(百万ドル) -22.53046
終値(lastsale) 5.01
時価総額(marketcap) 48724464.42
時価総額 時価総額(百万ドル) 44.34802
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -5.95137
当期純利益 当期純利益(百万ドル) 13.58047
決算概要 決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Caladrius Biosciences Inc revenues was not reported. Net loss before extraordinary items increased 5% to $9.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.96 to -$0.95.



   The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut  2019/11/08 13:14:09 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.
   Caladrius Biosciences to Participate at Upcoming November Conferences  2019/10/31 12:30:05 ACI Information Group
BASKING RIDGE, N.J., Oct. 31, 2019 -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company.
   Is Caladrius Biosciences (NASDAQ:CLBS) In A Good Position To Deliver On Growth Plans?  2019/10/23 15:30:33 ACI Information Group
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although…
   The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO  2019/10/10 11:31:01 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: …
   Caladrius Biosciences to Participate at the Upcoming October Conferences  2019/10/01 12:30:00 Yahoo Finance
BASKING RIDGE, N.J., Oct. 01, 2019 -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company.
   Caladrius Biosciences (CLBS) Investor Presentation - Slideshow  2019-05-01
The following slide deck was published by Caladrius Biosciences, Inc. in conjunction with this Read more …
   BTE, BRSS, WVE and FLXN among notable midday movers  2019-04-10
Gainers: Global Brass and Copper Holdings (NYSE: BRSS ) +25% . ATA (NASDAQ: ATAI ) +22% . Safe-T Group (NASDAQ: SFET ) +18% . TDH Holdings (NASDAQ: PETZ ) +17% . IZEA Worldwide (NASDAQ: IZEA ) +16% . Titan Medical (NASDAQ: TMDI ) +14% . Baytex Energy (NYSE: BTE ) +12% . Quorum Heal…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カラドリアス・バイオサイエンス CLBS Caladrius Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)